M&A Deal Summary |
|
---|---|
Date | 2017-08-28 |
Target | Calimmune |
Sector | Life Science |
Buyer(s) | CSL Behring |
Deal Type | Add-on Acquisition |
Deal Value | 91M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2000 |
Sector | Life Science |
CSL Behring LLC is a global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. CSL Behring LLC was established in 2000 and is based in King of Prussia, Pennsylvania.
DEAL STATS | # |
---|---|
Overall | 1 of 2 |
Sector (Life Science) | 1 of 2 |
Type (Add-on Acquisition) | 1 of 2 |
State (Arizona) | 1 of 1 |
Country (United States) | 1 of 1 |
Year (2017) | 1 of 1 |
Size (of disclosed) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2020-06-08 |
Vitaeris
Vancouver, British Columbia, Canada Vitaeris, Inc. is a clinical-stage biotechnology company focused on the phase III development of clazakizumab, an anti-interleukin-6 (IL-6) monoclonal antibody (MAB), for the potential treatment of chronic active antibody-mediated rejection (AMR), the leading cause of long-term rejection in kidney transplant recipients. Vitaeris was founded in 2016 and is based in Vancouver, British Columbia. |
Buy | - |